Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...

Hoth Therapeutics has shared phase 2 results on its treatment of EGFR inhibitor-induced skin toxicities, ticking off another ...

Deep-learning analysis of routine H&E slides accurately predicts key NSCLC driver mutations, supporting treatment in lung cancer care.

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

Major differences between eGFR based on cystatin C compared with creatinine were associated with higher rates for all-cause mortality, CV events and kidney failure for outpatients, according to data ...

Significant association seen for eGFR percentiles below the 25th percentile with risk for kidney failure with replacement ...

Chinese pharma Hansoh Pharma (HKEX: 3692) has secured approval from China’s National Medical Products Administration for an expanded use of its EGFR inhibitor Ameile (almonertinib). The decision ...

In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene ...